{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11000","value":"4070"},{"groupId":"OG001","spread":"2480","value":"1200"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"AUCinf represents the total drug exposure over time, extrapolated from the time of administration until the drug is completely eliminated from the body.","dispersionType":"Standard Deviation","groups":[{"description":"Eligible participants with relapsed or refractory acute lymphoblastic leukemia who had PK assessments on Day 8 of the induction cycle.","id":"OG000","title":"Carfilzomib - Day 8 Induction Cycle"},{"description":"Eligible participants with relapsed or refractory acute lymphoblastic leukemia who had PK assessments on Day 1 of the consolidation cycle.","id":"OG001","title":"Carfilzomib - Day 1 Consolidation Cycle"}],"paramType":"MEAN","populationDescription":"Phase 2 PK analysis set: All participants who received at least 1 dose of carfilzomib, had 1 PK sample collected and a quantifiable number of observations. Per SAP, analysis was not planned to compare T-cell and B-cell.","reportingStatus":"POSTED","timeFrame":"Day 8 of induction cycle (28-days cycle) and Day 1 of consolidation cycle (28-days cycle)","title":"Phase 2: AUCinf of Carfilzomib","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}